标题
Immunogenicity of CAR T cells in cancer therapy
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-02-25
DOI
10.1038/s41571-021-00476-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies
- (2020) LaQuisa C. Hill et al. BLOOD
- Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors
- (2020) Giovanni Fucá et al. CLINICAL CANCER RESEARCH
- CAR T-cell product performance in haematological malignancies before and after marketing authorisation
- (2020) Magdi Elsallab et al. LANCET ONCOLOGY
- Interleukin-23 engineering improves CAR T cell function in solid tumors
- (2020) Xingcong Ma et al. NATURE BIOTECHNOLOGY
- The therapeutic landscape for cells engineered with chimeric antigen receptors
- (2020) Matthew MacKay et al. NATURE BIOTECHNOLOGY
- Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
- (2020) Jennifer N. Brudno et al. NATURE MEDICINE
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
- (2020) Norris Lam et al. Nature Communications
- CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
- (2020) Nirali N. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9
- (2020) Ang Li et al. MOLECULAR THERAPY
- Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
- (2020) You Lu et al. NATURE MEDICINE
- Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy
- (2020) Yuki Kagoya et al. Cancer Immunology Research
- Engineered off-the-shelf therapeutic T cells resist host immune rejection
- (2020) Feiyan Mo et al. NATURE BIOTECHNOLOGY
- Metabolic engineering generates a transgene-free safety switch for cell therapy
- (2020) Volker Wiebking et al. NATURE BIOTECHNOLOGY
- Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
- (2020) Meenakshi Hegde et al. Nature Communications
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
- (2020) Jordan Gauthier et al. BLOOD
- Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis
- (2020) Andras Heczey et al. NATURE MEDICINE
- Secondary donor-derived humanized CD19-modified CAR-T cells induce remission in relapsed/refractory mixed phenotype acute leukemia after allogeneic hematopoietic stem cell transplantation: a case report
- (2020) Meng-Yun Li et al. Biomarker Research
- Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
- (2020) Reuben Benjamin et al. LANCET
- Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15
- (2019) Yuhui Chen et al. CLINICAL CANCER RESEARCH
- Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies
- (2019) Starlynn C. Clarke et al. Frontiers in Immunology
- Identification of preexisting adaptive immunity to Cas9 proteins in humans
- (2019) Carsten T. Charlesworth et al. NATURE MEDICINE
- Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
- (2019) Tobias Deuse et al. NATURE BIOTECHNOLOGY
- Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility
- (2019) Huaigeng Xu et al. Cell Stem Cell
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
- (2019) Ankit J. Kansagra et al. BONE MARROW TRANSPLANTATION
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
- (2019) Jing Pan et al. LEUKEMIA
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies
- (2019) Yu Zhao et al. CLINICAL CANCER RESEARCH
- Bystander activation and autoimmunity
- (2019) Yovana Pacheco et al. JOURNAL OF AUTOIMMUNITY
- Phase I study of lentiviral-transduced chimeric antigen receptor modified T cells recognizing mesothelin in advanced solid cancers
- (2019) Andrew R. Haas et al. MOLECULAR THERAPY
- Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
- (2019) Tania Jain et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
- (2019) Sara Ghorashian et al. NATURE MEDICINE
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
- (2019) Lekha Mikkilineni et al. BLOOD
- Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- (2019) Ibrahim Yakoub-Agha et al. HAEMATOLOGICA
- A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel
- (2019) Bernd Potthoff et al. JOURNAL OF IMMUNOLOGICAL METHODS
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia
- (2018) Jiang Cao et al. AMERICAN JOURNAL OF HEMATOLOGY
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities
- (2018) Thomas Shum et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects
- (2018) Yuki Kagoya et al. NATURE MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of Pre-existing Antibodies to CRISPR-Associated Nuclease Cas9 in the USA Population
- (2018) Vijaya L. Simhadri et al. Molecular Therapy-Methods & Clinical Development
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
- (2018) Dimitrios L. Wagner et al. NATURE MEDICINE
- Making CAR T Cells a Solid Option for Solid Tumors
- (2018) Andrea Schmidts et al. Frontiers in Immunology
- A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
- (2018) Dina Schneider et al. Frontiers in Oncology
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
- (2017) Ifigeneia Tzannou et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells
- (2017) Lynsey M. Whilding et al. MOLECULAR THERAPY
- HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells
- (2017) Germán G Gornalusse et al. NATURE BIOTECHNOLOGY
- Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
- (2017) Paul M Maciocia et al. NATURE MEDICINE
- CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
- (2017) Terry J Fry et al. NATURE MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma
- (2017) Nan Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
- (2017) Thomas Shum et al. Cancer Discovery
- Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18
- (2017) Biliang Hu et al. Cell Reports
- mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
- (2017) Jason J. Lohmueller et al. OncoImmunology
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
- (2017) Kristen M. Hege et al. Journal for ImmunoTherapy of Cancer
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
- (2016) Jiangtao Ren et al. CLINICAL CANCER RESEARCH
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
- (2016) Richard P. Junghans et al. PROSTATE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
- (2015) M. Mamonkin et al. BLOOD
- Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
- (2015) X. Zhou et al. BLOOD
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
- (2015) Mahesh Jonnalagadda et al. MOLECULAR THERAPY
- Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
- (2015) Xiao-Hui Zhang et al. Molecular Therapy-Nucleic Acids
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical Recommendations
- (2014) G. Shankar et al. AAPS Journal
- Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
- (2014) A. Heczey et al. BLOOD
- Interleukin-13 Receptor Alpha 2-Targeted Glioblastoma Immunotherapy
- (2014) Sadhak Sengupta et al. Biomed Research International
- Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation
- (2013) Eric Spierings et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
- (2013) A. M. Leen et al. BLOOD
- Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
- (2013) H. Torikai et al. BLOOD
- Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells
- (2013) M. Hudecek et al. CLINICAL CANCER RESEARCH
- The immunogenicity of virus-derived 2A sequences in immunocompetent individuals
- (2013) C Arber et al. GENE THERAPY
- Bispecific T-cells Expressing Polyclonal Repertoire of Endogenous γδ T-cell Receptors and Introduced CD19-specific Chimeric Antigen Receptor
- (2013) Drew C Deniger et al. MOLECULAR THERAPY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells
- (2013) Yanfang Fu et al. NATURE BIOTECHNOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
- (2013) G. L. Beatty et al. Cancer Immunology Research
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
- (2012) B. G. Till et al. BLOOD
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
- (2012) J. Scholler et al. Science Translational Medicine
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
- (2011) Antonio Di Stasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
- (2010) C. H. J. Lamers et al. BLOOD
- Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects
- (2010) J. J. Melenhorst et al. BLOOD
- Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response
- (2010) A Hombach et al. GENE THERAPY
- How to systematically evaluate immunogenicity of therapeutic proteins – regulatory considerations
- (2009) Eva-Maria Jahn et al. New Biotechnology
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
- (2008) B. G. Till et al. BLOOD
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
- (2008) Martin A Pule et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started